Login to Your Account



AVEO, Astellas Seek to Hang Tivozanib Hat on PFS Data

By Marie Powers
Staff Writer

Wednesday, January 4, 2012
AVEO Pharmaceuticals Inc. and partner Astellas Pharma Inc. reported top-line data from the global, randomized Phase III TIVO-1 trial indicating that lead compound tivozanib demonstrated superiority over Nexavar (sorafenib, Onyx) in advanced renal cell carcinoma (RCC), meeting the primary endpoint of progression-free survival (PFS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription